We are recruiting participants (12 years and older) in clinical trials for USH2A mediated Usher syndrome and Retinitis Pigmentosa. Check if you're eligible!
ProQR is recruiting people with Fuchs endothelial corneal dystrophy for a clinical study of an investigational RNA therapy. Learn more about the study and how to participate.
ProQR is recruiting children under 8 years old with Leber congenital amaurosis for a clinical study of an investigational RNA therapy. Learn more about the study and how to participate.
See the ongoing and planned clinical trials and how you can contribute to research. Contact us for more information or for clinical trial participation.
ProQR has conducted a clinical trial of an investigational RNA therapy for people with retinitis pigmentosa. Learn more about the study and its results.
ProQR is conducting a pivotal clinical study of an investigational RNA therapy for people with Leber congenital amaurosis (LCA10). Learn more about the study and the sepofarsen program.
Two Phase 2/3 clinical trials aim to validate ultevursen’s ability to stop vision loss in retinitis pigmentosa and Usher syndrome. Learn more about the trials here.
In a Phase 1/2 clinical trial investigational RNA therapy QR-1123 showed target engagement. ProQR plans to start a Phase 2 study for RHO mediated retinitis pigmentosa.
The clinical trial named Brighten evaluates the safety and tolerability of investigational RNA therapy sepofarsen in children with Leber congenital amaurosis.
A blog by Martin Hills from Retina UK living with Retinitis Pigmentosa on why research participation and genetic testing are essential in for drug development and how to get involved.
